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Abstract
Our recent study identiﬁed a list of differentially expressed microRNAs (miRNAs) in human prostate cancer (PCa) tissues
compared to adjacent benign prostate tissues. In the current study, to identify the crucial miRNA–mRNA regulatory
biomodule involved into prostate carcinogenesis based on the previous miRNA expression proﬁle in PCa, we
proposed an integrated systematic approach which combined miRNA-mediated gene expression regulatory network
analysis, experimental validations in vitro and in vivo, as well as clinical signiﬁcance evaluation. As a result, the CCND1-
RNASEL-CDKN1A-TP73-MDM2-UBE2I axis was identiﬁed as a bottleneck in the miRNA-mediated gene expression
regulatory network of PCa according to network topological analysis. The direct binding relationship between TP73
and PCa downregulated miR-193a-5p, and the direct binding relationship between UBE2I and PCa upregulated miR-
188-5p were both experimentally validated. In addition, miR-193a-5p had a more signiﬁcant regulatory effect on the
tumor promoter isoform of TP73-deltaNp73 than on the tumor suppressive isoform of TP73-TAp73. Importantly, the
deregulation of either the miR-193a-5p-TP73 or miR-188-5p-UBE2I axes was signiﬁcantly associated with aggressive
progression and poor prognosis in PCa patients. Gain- and loss-of-function experiments showed that miR-193a-5p
efﬁciently inhibited in vitro PCa cell proliferation, migration, and invasion, and in vivo tumor growth, and markedly
induced PCa cell apoptosis via regulating TP73 with a corresponding suppression of the CCND1-RNASEL-CDKN1A-
MDM2 axis. In contrast, miR-188-5p exerted its tumor promoter roles through targeting UBE2I with a subsequent
activation of the CCND1-RNASEL-CDKN1A-MDM2 axis. Taken together, this integrated analysis revealed the potential
roles of the miR-193a-5p/TP73 and miR-188-5p/UBE2i negative regulation pairs in PCa. In addition to the signiﬁcant
clinical relevance, miR-193a-5p- and miR-188-5p-regulated CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I signaling may
be a novel regulatory biomodule in prostate carcinogenesis.
Introduction
Prostate cancer (PCa) is one of the most frequently
diagnosed cancers among men and is the second leading
cause of male cancer-related deaths1. PCa progresses in
an androgen-dependent manner and responds to hor-
mone deprivation/ablation therapy that subsequently
removes circulating androgens and reduces androgen
action2. However, many patients do not respond well to
this treatment and even progress to an androgen-
independent state, which is more aggressive and treat-
ment resistant3. Despite an increasing use of prostate-
speciﬁc antigen (PSA)-based screening for early detection
of PCa at a curable stage, determining which patients
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require treatment and what types of therapy should be
performed remain challenging. More efﬁcient and novel
biomarkers should be identiﬁed and used to conﬁrm the
malignant potentials of PCa to predict patient clinical
outcome, evaluate the risk of recurrence and select opti-
mized therapeutic strategies.
Accumulating studies have identiﬁed multiple dysre-
gulated microRNAs (miRNAs), which are hallmark
characteristics during prostate carcinogenesis4–6. How-
ever, the complexity of how a single miRNA can play
numerous roles in carcinogenesis, speciﬁcally in PCa, has
not been fully elucidated.
Ribonuclease L (RNASEL), which is located on chro-
mosome 1q25a, is a uniquely regulated endoribonuclease
that is involved in the cleavage of viral RNA and the
interferon-mediated immune response7. Several
population-based case-control studies have investigated
the associations between RNASEL variants and PCa
risk8–10. These ﬁndings suggest that RNASEL may play a
crucial role in PCa. However, little is known about the
underlying molecular mechanisms through which RNA-
SEL affects PCa.
Our recent study identiﬁed 26 differentially expressed
miRNAs between PCa and adjacent benign tissues
obtained from PCa patients6. To identify the crucial
miRNAs based on this previous miRNA expression proﬁle
in PCa and their target genes and to decipher the
potential relationship between the changes in the
expression of these miRNAs and RNASEL, we proposed
an integrated systematic approach to illustrate an
miRNA-mediated gene expression regulatory network,
discover crucial miRNA-target negative regulation pairs
with network topological importance, validate their bio-
logical functions based on in vitro and in vivo experi-
mental systems and evaluate their clinical signiﬁcance in
human PCa. A schematic diagram of this study is pro-
vided in Supplementary Figure S1.
Results
Signal axis screening of the miRNA-mediated regulatory
network of PCa
Signal axis screening
In our previous study, 26 differentially expressed miR-
NAs, including 9 upregulated and 17 downregulated
miRNAs (all fold change ≥ 1.5; P ≤ 0.05), were identiﬁed
through a comparison of PCa and adjacent benign pros-
tate tissues6. Detailed information for these differentially
expressed miRNAs is provided in Supplementary
Table S1. The common results of three miRNA target-
predicting programs (TargetScan, miRWalk, and miR-
anda) identiﬁed 593 candidate miRNA–mRNA pairs
based on the putative interactions between differentially
expressed miRNAs and target genes as well as between
miRNAs and RNASEL, as shown in Supplementary
Table S2. The biological signiﬁcance of these
miRNA–mRNA pairs is provided in Supplementary
File S1—section 1 and Figure S2.
A miRNA-mediated regulatory network of PCa was
constructed using the links among putative target genes of
differentially expressed miRNAs and RNASEL-upstream
miRNAs. This network contained 243 nodes and 1167
edges (Supplementary Table S3). Following the calcula-
tion of four topological features, including ‘Degree,’ ‘Node
betweenness’ and ‘Closeness’ and ‘K coreness,’ 89 hubs
with topological importance were chosen, and the hub
network was also constructed based on the direct inter-
actions among hubs. Detailed information about the
topological features of the hubs is provided in Supple-
mentary Table S4.
Because genes with close interconnections are often
involved in the same functional modules or pathways,
modularity may be another important aspect of an
interaction network. In the current study, we performed
modularity analysis using the Markov clustering algo-
rithm and divided the above-mentioned hub network into
the following three functional modules: ‘Cell cycle, Path-
ways in cancer, and P53 signaling pathway’ (48 nodes);
‘MAPK signaling pathway and Focal adhesion’ (38 nodes);
and ‘VEGF signaling pathway’ (3 nodes) (Supplementary
Figure S3).
Moreover, the ‘Edge-betweenness’ of each interaction in
the hub network was calculated because an interaction
with a high ‘Edge-betweenness’ is deﬁned as a bottleneck
that has many ‘shortest paths’ going through it and con-
trols the rate of information ﬂow. As shown in Supple-
mentary Table S5, the interaction between CCND1-
CDKN1A had the highest ‘Edge-betweenness’ value
(40.10), implying its importance in connecting different
functional modules within the network.
Among the putative targets of differentially expressed
miRNAs in PCa, TP73 was a putative target of miR-193a-
5p (PCa-downregulated miRNA, Supplementary
Table S1) and interacted with CDKN1A. Additionally,
UBE2I was a putative target of miR-188-5p (PCa-upre-
gulated miRNA, Supplementary Table S1) and interacted
with TP73 and CDKN1A through MDM2 (Fig. 1a).
Moreover, we also found 17 miRNAs that act upstream of
RNASEL and were shared with CCND1 and/or CDKN1A,
implying similar functions among the three genes
(Fig. 1a). Thus, we hypothesized that the signal axis of
CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I might
play a crucial role in the miRNA-mediated regulatory
network of human PCa.
Biological signiﬁcance of the CCND1-RNASEL-CDKN1A-TP73-
MDM2-UBE2I signal axis
Cyclin D1 (CCND1) is ampliﬁed and overexpressed in a
variety of human malignancies, including human PCa11,12.
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In accordance with the androgen dependence of PCa,
CCND1 interacts with the androgen signaling pathway,
suggesting that androgens may indirectly stimulate cell
growth via regulating the expression of cell cycle-
associated genes13.
CDKN1A (also called p21), which is a CDK inhibitor
(CKI), can suppress the effects of the CCND1-CDK4
complex in the G1 phase, leading to G1 arrest. Impor-
tantly, p21 activation requires high levels of tumor protein
p73 (TP73)14.
TP73 encodes a variety of protein isoforms with
opposing functions via alternative promoters at the 5′-end
or differential splicing at the 3′-end15,16. Among the iso-
forms, TAp73 variants, which contain the NH2-terminal
transactivation domain, are tumor suppressors and mimic
TP53 function in experimental systems. In contrast, del-
taNp73 variants, which are transactivation-deﬁcient iso-
forms, function as oncogenes and cannot induce
apoptosis and cell cycle arrest because they are direct
competitors for the DNA-binding sites and/or they form
hetero-duplexes with TP53 and the transactivation-
competent TAp73 variants17. Hence, the biological func-
tions of miRNAs that directly target TP73 may depend on
which isoforms they mainly regulate. Moreover,
Guan et al.18 observed a signiﬁcant increase of deltaNp73
in PCa tissues compared with benign prostate hyperplasia
tissues and conﬁrmed that the incidence of positive
expression of deltaNp73 is correlated with the Gleason
score in PCa.
RNASEL regulates p21-mediated G1 growth arrest in an
AU-rich element-dependent manner. Overexpression of
RNASEL may activate p2119.
Ubiquitin-conjugating enzyme E2 I (UBE2I) encodes a
member of the E2 ubiquitin-conjugating enzyme family
(UBC9), which may modify proteins with ubiquitin, a
crucial cellular mechanism for targeting abnormal or
short-lived proteins for degradation. A previous study
based on a yeast two-hybrid system found that RAD52-
dependent processes, cell cycle control, p53-mediated
pathway(s), and ubiquitination interact through human
UBE2I20.
We illustrated a model to hypothesize the involvement
of the miR-193a-5p-regulated and miR-188-5p-regulated
CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I signal
axis in prostate carcinogenesis (Fig. 1b). In PCa tissues,
the increased expression of miR-188-5p may negatively
regulate the expression of its candidate target gene,
UBE2I, which may reduce the degradation of TP73.
Simultaneously, the downregulation of miR-193a-5p in
PCa tissues might result in the upregulation of TP73.
Because there are different isoforms of TP73 with varying
potential for tumor progression, TP73 may play opposite
roles depending on changes in the TAp73/ deltaNp73
isoform ratio. If the TAp73/deltaNp73 isoform ratio is
increased by miR-193a-5p in PCa cells, the expression
levels of MDM2 and P21 (CDKN1A) might be elevated,
and TP73 might function as a tumor suppressor, leading
to the reduced effect of the CCND1/CDK4 complex and
Fig. 1 Involvement of the miR-193a-5p and miR-188-5p-regulated CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I signal axis in prostate
cancer (PCa) cells. a Sub-network of the CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I signal axis and the corresponding upstream microRNAs.
Nodes with a red border refer to an upregulated microRNA in PCa. Nodes with a blue border refer to a downregulated microRNA in PCa. Nodes with
a yellow border refer to common microRNAs upstream of CCND1, RNASEL and CDKN1A. b Molecular model of the miR-193a-5p and miR-188-5p-
regulated CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I signal axis in PCa cells
Zhang et al. Cell Death and Disease  (2018) 9:301 Page 3 of 14
Ofﬁcial journal of the Cell Death Differentiation Association
G1 arrest. If the TAp73/deltaNp73 isoform ratio is
decreased by miR-193a-5p in PCa cells, the expression
levels of MDM2 and P21 (CDKN1A) might be reduced,
and TP73 might function as an oncogene. Taken together,
an imbalance of the miR-193a-5p- and miR-188-5p-
regulated CCND1-RNASEL-CDKN1A-TP73-MDM2-
UBE2I biomodule might be involved in prostate
carcinogenesis.
Deregulation of miR-193a-5p-TP73 and miR-188-5p-UBE2I
pairs associated with aggressive progression and poor
prognosis in PCa patients
To evaluate the associations of miR-193a-5p-TP73 and
miR-188-5p-UBE2I expression with various clin-
icopathological features of PCa patients, the optimal
cutoff points of miR-193a-5p, TP73, miR-188-5p and
UBE2I expression were screened. The optimal cutoff
point was deﬁned with regard to the miRNA/mRNA
expression level either alone or in combination with the
most signiﬁcant BCR-free survival. Using the optimal
cutoff points, 490 PCa patients were divided into miR-
193a-5p-high/low, TP73-high/low, miR-188-5p-high/low
and UBE2I-high/low groups. As shown in Table 1, high
TP73 expression was signiﬁcantly associated with disease-
free status (P= 0.042), and low miR-193a expression
combined with high TP73 expression frequently occurred
in PCa patients with advanced T-stage (P= 0.047) and
positive disease recurrence (P= 0.031). In addition, PCa
patients with high miR-188-5p or low UEB2I expression
had a higher incidence of biochemical recurrence than
those with low miR-188-5p or high UBE2I expression
(both P< 0.05). Gleason grades of PCa patients with high
miR-188-5p expression and miR-188-5p-high/UBE2I-low
expression were signiﬁcantly higher than those of patients
with low miR-188-5p expression and miR-188-5p-low/
UBE2I-high expression, respectively (both P< 0.05). Both
low UBE2I expression and combined miR-188-5p-high/
UBE2I-low expression were signiﬁcantly associated with
advanced T stage (both P< 0.05). PCa patients with miR-
188-5p-high/UBE2I-low expression frequently experi-
enced advanced N stage and recurred/progressed disease
status (both P< 0.05, Table 1).
Table 1 Association of two miRNA–mRNA pairs with clinicopathologic features of prostate cancer patients based on
TCGA data




(n, %) P (n, %) P (n, %) P (n, %) P (n, %) P (n, %) P
Age (years)
<55 83 18 (21.7) 0.883 56 (67.5) 0.265 13 (37.1) 0.422 40 (48.2) 0.698 38 (45.8) 0.162 19 (43.3) 0.405
>55 406 85 (20.9) 245(60.3) 53 (29.1) 204 (50.2) 206 (50.7) 101 (51.3)
Biochemical-recurrence status
Negative 365 78 (21.4) 0.499 227 (62.2) 1.000 48 (30.8) 0.516 160 (43.8) 0.033 167 (45.8) 0.035 79 (45.9) 1.000
Positive 59 15 (25.4) 37 (62.7) 11 (37.9) 40 (67.8) 40 (67.8) 14 (46.7)
Gleason pattern (Primary)
Grade 3 191 34 (17.8) 0.310 120 (62.8) 0.114 20 (26.0) 0.275 78 (40.8) 0.018 98 (51.3) 0.100 44 (44.4) <0.001
Grade 4 248 59 (23.8) 144 (58.1) 36 (30.8) 129 (52.0) 116 (46.8) 60 (48.0)
Grade 5 49 10 (20.4) 36 (73.5) 10 (43.5) 38 (77.6) 30 (61.2) 16 (100.0)
T-stage
<T2 176 30 (17.0) 0.210 105 (59.7) 0.299 16 (21.9) 0.047 87 (49.4) 0.386 75 (42.6) 0.003 39 (42.4) 0.007
>T2 226 51 (22.6) 147 (65.0) 39 (36.8) 113 (50.0) 140 (61.9) 69(62.2)
N-stage
N0 339 71 (20.9) 0.545 207 (61.1) 0.798 44 (29.5) 0.342 168 (49.6) 0.882 165 (48.7) 0.061 72 (43.6) <0.001
N1 79 19 (24.1) 50 (63.3) 15 (37.5) 40 (50.6) 46 (58.2) 28(82.4)
Disease-free status
Free 392 79 (20.2) 0.318 233 (59.4) 0.042 48 (27.3) 0.031 189 (48.2) 0.562 188 (48.0) 0.052 89 (46.6) 0.038
Recurred/progressed 91 23 (25.3) 65 (71.4) 17 (45.9) 52 (57.1) 56 (61.5) 32 (64.0)
a Some clinical features lack the information, so the total numbers according to various features are different
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The prognostic values of miR-193a-5p and/or TP73
expression as well as miR-188-5p and/or UBE2I expres-
sion in PCa patients were evaluated using the
Kaplan–Meier method based on TCGA data. As shown in
Fig. 2h, i, high TP73 expression alone or in combination
with low miR-193a expression were both signiﬁcantly
associated with short BCR-free survival when compared
with low TP73 expression (P= 0.036) and miR-193a-5p-
high /TP73-low expression (P= 0.033) groups, respec-
tively. Moreover, only miR-188-5p-high/UBE2I-low
expression was signiﬁcantly associated with short BCR-
free survival (P= 0.045, log-rank test, Fig. 2l). There were
no signiﬁcant prognostic values of miR-193a-5p/TP73
and miR-188-5p/UBE2I axes in overall and disease
metastasis-free survivals (Fig. 2a–f and Fig. 2m–r).
TP73 and UBE2I are respective direct targets of miR-193a-
5p and miR-188-5p in PCa cells
The results shown in Supplementary Figure S4A indi-
cated that the endogenous expression of TP73 in PCa
cells and in established tumors associated with LNCaP
cells stably expressing miR-193a-5p was signiﬁcantly
reduced at both the mRNA and protein levels. In contrast,
knockdown of miR-193a-5p by its inhibitor efﬁciently
increased the expression of TP73 mRNA and protein in
both PCa cells and established tumors (Supplementary
Figure S4A). The ﬁndings for the miR-188-5p/UBE2I pair
were similar to those for the miR-193a-5p/TP73 pair
(Supplementary Figure S4B). Because TP73 has various
isoforms with opposing functions, we performed qRT-
PCR to evaluate the regulatory effects of miR-193a-5p on
a tumor promoter isoform of TP73 (deltaNp73) and a
tumor suppressive isoform of TP73 (TAp73). As shown in
Supplementary Figure S5, the enforced expression of miR-
193a-5p in PCa cells effectively reduced the expression of
deltaNp73 mRNA and increased the ratio of TAp73 to
deltaNp73. In contrast, the suppression of miR-193a-5p
upregulated the expression of deltaNp73 mRNA and
decreased the ratio of TAp73 to deltaNp73. These results
suggest a more signiﬁcant regulatory effect of miR-193a-
5p on deltaNp73 than on TAp73.
To verify whether TP73 was a direct target of miR-193a-
5p, and UBE2I was a direct target of miR-188-5p, a luci-
ferase reporter containing the complimentary seed
sequences of miR-193a-5p/miR-188-5p at the 3′-UTR
region of TP73 (Transcript NM_001126242, protein
name: deltaNp73 gamma) /UBE2I (Transcript
NM_003345) mRNA was constructed. At 48 h after
transfection, luciferase activity of the TP73 reporter was
signiﬁcantly reduced by co-transfection with miR-193a-5p
mimics. In contrast, the luciferase activity of the TP73
reporter containing the mutated sequence of the same
fragment was not affected by co-transfection with miR-
193a-5p mimics (Supplementary Figure S6A). These
ﬁndings were similar with those for the miR-188-5p/
UBE2I pair (Supplementary Figure S6B).
Fig. 2 Overall survival (a–f), biochemical recurrence (BCR)-free survival (g–l) and distant-metastasis-free survival (m–r) curves based on miR-193a and/
or TP73 as well as miR-188 and/or UBE2I expression in patients with prostate cancer based on TCGA data
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The above data suggest that TP73 and UBE2I may be
direct targets of miR-193a-5p and miR-188-5p, respec-
tively, in PCa cells.
miR-193a-5p functions as a tumor suppressor in PCa via
targeting TP73
CCK-8 assays indicated that proliferation rate of LNCaP
and PC3 cells transfected with miR-193a-5p mimics was
signiﬁcantly lower than those transfected with the nega-
tive control (Fig. 3a and Supplementary Figure S7A).
Transwell assays showed that the enforced expression of
miR-193a-5p signiﬁcantly reduced the invasive activities
of both LNCaP and PC3 cells (Fig. 3b and Supplementary
Figure S7B). Wound-healing assays also revealed that
miR-193a-5p overexpression efﬁciently weakened the
migratory abilities of both LNCaP and PC3 cells (Fig. 3c
and Supplementary Figure S7C). Based on the in vivo
system, we found that the LNCaP cells stably expressing
miR-193a-5p formed signiﬁcantly smaller tumor nodules
and showed markedly slow growth of tumor xenografts
(Fig. 3d). In contrast, the apoptotic rates of LNCaP and
PC3 cells with miR-193a-5p upregulation were sig-
niﬁcantly higher than those of control cells (Fig. 3e and
Supplementary Figure S7D). Interestingly, knockdown of
miR-193a-5p expression by the corresponding inhibitor
efﬁciently enhanced the cellular proliferation, invasion
ability and motility of PCa cells and promoted the growth
of tumor xenografts; it reduced cellular apoptosis in vitro
(Fig. 3f–j and Supplementary Figure S7E–H).
To determine the roles of TP73 in biological functions
of miR-193a-5p, pCDNA3.1(+) vectors expressing TP73
without its 3′-UTR (using the binding site of 3′UTR of
Fig. 3 miR-193a-5p inhibits LNCaP cell proliferation, migration and invasion and in vivo tumor growth, but it induces LNCaP cell
apoptosis. a The CCK-8 assay indicated that proliferation of LNCaP cells transfected with miR-193a-5p mimics was signiﬁcantly reduced compared
with that of cells transfected with the negative control. b The transwell assay showed that the enforced expression of miR-193a-5p signiﬁcantly
reduced the invasive activities of LNCaP cells compared with those of control cells. c The wound-healing assay revealed that miR-193a-5p
overexpression efﬁciently weakened the migratory ability of LNCaP cells. d Based on the in vivo system, LNCaP cells stably expressing miR-193a-5p
formed signiﬁcantly smaller tumor nodules and showed markedly slow growth of tumor xenografts compared with the controls. e The apoptotic rate
of LNCaP cells with miR-193a-5p upregulation was signiﬁcantly higher than that of control cells. f–j Knockdown of miR-193a-5p expression with the
corresponding inhibitor efﬁciently enhanced the cellular proliferation, invasion ability and motility of LNCaP cell lines and promoted the growth of
tumor xenografts, but it reduced cellular apoptosis in vitro. Note: ‘×10’ and ‘×20’ refer to the magniﬁcation
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Transcript NM_001126242, the protein name of which is
deltaNp73 gamma) were generated. As shown in Fig. 4a
and Supplementary Figure S8A, the endogenous expres-
sion of TP73 protein in LNCaP and PC3 cells transfected
with miR-193a-5p mimics in the presence of pCDNA3.1-
TP73 was signiﬁcantly higher than that in cells transfected
with miR-193a-5p and vector control. In vitro cellular
proliferation (Fig. 4b and Supplementary Figure S8B),
invasion (Fig. 4c and Supplementary Figure S8C), migra-
tion (Fig. 4d and Supplementary Figure S8D) and apop-
tosis (Fig. 4e and Supplementary Figure S8E) all indicated
that restoration of TP73 expression dramatically atte-
nuated the effects induced by miR-193a-5p.
These ﬁndings suggest that the tumor suppressive roles
of miR-193a-5p may be mediated by inhibiting its target
gene, TP73.
miR-188-5p functions as an onco-miRNA in PCa by
targeting UBE2I
CCK-8 assays indicated that proliferation rates of
LNCaP and PC3 cells were signiﬁcantly increased by
transfection with miR-188-5p mimics (Fig. 5a and Sup-
plementary Figure S9A). Transwell and wound-healing
assays showed that the enforced expression of miR-188-
5p dramatically enhanced the invasive and migratory
activities, respectively, of both LNCaP and PC3 cells
(Figure 5b, c and Supplementary Figure S9B, C). Based on
the in vivo system, miR-188-5p overexpression promoted
tumor growth (Fig. 5d). In contrast, the apoptotic rates of
LNCaP and PC3 cells with miR-188-5p upregulation were
signiﬁcantly lower than those of control cells (Fig. 5e and
Supplementary Figure S9D). Interestingly, knockdown of
miR-188-5p expression by the corresponding inhibitor
Fig. 4 Re-expression of TP73 rescues the tumor suppressive effects of miR-193a-5p in LNCaP cells. a Endogenous TP73 protein expression
levels were detected by western blotting in LNCaP cells transfected with the miR-193a-5p mimic in the presence of TP73 or vector control for 48 h.
b–e Expression of TP73 using a construct lacking its 3′-UTR rescued the biological effects associated with re-introduction of miR-193a-5p, as indicated
by cell invasion, viability, migration and apoptosis assays. These experiments were performed after transfection of miR-193a-5p mimics and/or the
TP73 3′-UTR (−) for 48 h. The data are representative of at least three independent experiments and are presented as the mean ± s.e.m. Note: ‘×10’
and ‘×20’ refer to the magniﬁcation
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reduced the enhanced effects on cellular proliferation,
invasion and motility of PCa cell lines and the growth of
tumor xenografts, but it increased cellular apoptosis
in vitro (Fig. 5f–j and Supplementary Figure S9E–H).
In the rescue experiments, the endogenous expression
of UBE2I protein in LNCaP and PC3 cells transfected with
miR-188-5p mimics in the presence of pCDNA3.1-UBE2I
was signiﬁcantly higher than that in cells transfected with
miR-188-5p and vector control (Fig. 6a and Supplemen-
tary Figure S10A). In vitro cellular proliferation (Fig. 6b
and Supplementary Figure S10B), invasion (Fig. 6c and
Supplementary Figure S10C), migration (Fig. 6d and
Supplementary Figure S10D), and apoptosis (Fig. 6e and
Supplementary Figure S10E) all indicated that restoration
of UBE2I expression dramatically attenuated the effects
induced by miR-188-5p.
These ﬁndings suggest that the onco-miRNA roles of
miR-188-5p may be mediated by inhibiting its target gene,
UBE2I.
CCND1, RNASEL, CDKN1A, and MDM2 function as the
downstream effectors of the miR-193a-5p-TP73 and miR-
188-5p-UBE2I axes
According to our above-mentioned network analysis,
the CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I
axis may play crucial roles in the imbalanced miRNA-
mediated regulatory network of human PCa. After vali-
dation of the clinical signiﬁcance and the biological
functions of the miR-193a-5p-TP73 and miR-188-5p-
UBE2I axes, we investigated their regulatory effects on
the protein expression levels of CCND1, RNASEL,
CDKN1A, and MDM2 by western blot analysis. As
shown in Fig. 7a and b, the enforced expression of miR-
193a-5p in two PCa cell lines, LNCaP and PC3, sig-
niﬁcantly reduced the protein expression levels of TP73,
CCND1 and MDM2 but increased the protein expres-
sion levels of RNASEL and CDKN1A (all P < 0.05). In
contrast, miR-188-5p overexpression markedly increased
the protein expression levels of CCND1 and MDM2 but
Fig. 5 miR-188-5p promotes LNCaP cell proliferation, migration and invasion and in vivo tumor growth, but it suppresses LNCaP cell
apoptosis. a The CCK-8 assay indicated that the proliferation of LNCaP cells transfected with miR-188-5p mimics was signiﬁcantly greater than that
of cells transfected with the negative control. b The transwell assay showed that the enforced expression of miR-188-5p signiﬁcantly enhanced the
invasive activities of LNCaP cells compared with those of control cells. c The wound-healing assay revealed that miR-188-5p overexpression efﬁciently
enhanced the migratory ability of LNCaP cells. d The apoptotic rate of LNCaP cells with miR-188-5p upregulation was signiﬁcantly lower than that of
control cells. e–h Knockdown of miR-188-5p expression by the corresponding inhibitor efﬁciently weakened the cellular proliferation, invasion ability
and motility of LNCaP cell lines and inhibited the growth of tumor xenografts, but it enhanced cellular apoptosis qin vitro. Note: ‘×10’ and ‘×20’ refer
to the magniﬁcation
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decreased the protein expression levels of UBE2I,
RNASEL and CDKN1A (all P < 0.05). In addition, the
expression levels of CCND1 and MDM2 proteins were
dramatically upregulated, but the expression levels of
RNASEL and CDKN1A proteins were signiﬁcantly
downregulated, in LNCaP and PC3 cells with the over-
expression of TP73 (all P < 0.05, Fig. 7c), which were
opposite to the miR-193a-5p enforced cells. Moreover,
the enforced expression of UBE2I in two PCa cell lines
markedly reduced the protein expression levels of
CCND1 and MDM2 but increased the protein expres-
sion levels of RNASEL and CDKN1A (all P < 0.05,
Fig. 7d), which were also opposite to the miR-188-5p
enforced cells as mentioned above. Furthermore, the
qPCR analysis shown in Supplementary Figure S11 also
indicated the similar results to the western blot as
mentioned above (Fig. 7). These ﬁndings suggest that
CCND1, RNASEL, CDKN1A, and MDM2 may function
as the downstream effectors of the miR-193a-5p-TP73
and miR-188-5p-UBE2I axes.
Fig. 6 Re-expression of UBE2I rescues the oncogenic effects of miR-188-5p in LNCaP cells. a Endogenous UBE2I protein expression levels were
detected by western blotting in LNCaP cells transfected with the miR-188-5p mimic in the presence of UBE2I or vector control for 48 h. b–e
Expression of UBE2I using a construct lacking its 3′-UTR rescued the biological effects associated with re-introduction of miR-188-5p, as indicated by
cell invasion, viability, migration and apoptosis assays. These experiments were performed after co-transfection of miR-188-5p mimics and/or the
UBE2I 3′-UTR (−) for 48 h. The data are representative of at least three independent experiments and are presented as the mean ± s.e.m. Note: ‘×10’
and ‘×20’ refer to the magniﬁcation
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Fig. 7 (See legend on next page.)
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Discussion
miRNA dysregulation is a hallmark characteristic dur-
ing prostate carcinogenesis. However, the underlying
mechanisms of the miRNA-regulated oncogenic biomo-
dules in PCa have not been fully elucidated. Previously, we
identiﬁed a list of aberrantly expressed miRNAs based on
a clinical cohort of PCa patients using an miRNA
microarray approach. In this study, we constructed an
miRNA-mediated gene expression regulatory network of
PCa and identiﬁed a novel miRNA–mRNA regulatory
biomodule of miR-193a-5p- and miR-188-5p-regulated
CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I sig-
naling. Following network topological analysis, clinical
signiﬁcance evaluation and a series of functional experi-
mental validations, we demonstrated that an imbalance in
this biomodule may be implicated in prostate carcino-
genesis, progression and patient prognosis.
Accumulating studies have reported the downregulation
of miR-193a in various human cancers and revealed
its involvement in carcinogenesis and cancer progres-
sion21–25. Similarly, our clinical analysis showed that
dysregulation of the miR-193a/TP73 axis was closely
correlated with advanced T-stage and positive disease
recurrence. In addition, the BCR-free survival of PCa
patients with miR-193a-5p-low/TP73-high expression
was shorter than that of patients with miR-193a-5p-high/
TP73-low expression. Functional experiments identiﬁed
TP73 as a target gene of miR-193a-5p and conﬁrmed the
TP73-mediated tumor suppressive roles of the miR-193a-
5p/TP73 axis in malignant PCa cell lines. More interest-
ingly, Jacques et al.25 found that miR-193a-5p controls
Cisplatin chemoresistance in primary bone tumors via
TAp73β. However, our data showed a more signiﬁcant
regulatory effect of miR-193a-5p on deltaNp73 (a tumor
promoter isoform of TP73) than on TAp73 (a tumor
suppressive isoform of TP73), implying different reg-
ulatory mechanisms of miR-193a-5p across cancer types.
miR-188, a cancer-related miRNA, functions as a tumor
suppressor in oral squamous cell carcinoma26 and hepa-
tocellular carcinoma27. Notably, Zhang et al.28 suggested
that miR-188-5p might exert tumor suppressor functions
in the carcinogenesis of PCa, which disagrees with our
ﬁndings. The reasons for this discrepancy might are
explained below. First, the microarray data showing the
marked upregulation of miR-188-5p in PCa tissues
compared with adjacent non-cancerous prostate tissues
were based on clinical samples. In contrast, Zhang’s
miRNA array data displaying the decreased expression of
miR-188-5p were obtained from paired metastatic LTL-
313H and non-metastatic LTL-313B PCa xenografts.
Second, the TCGA data set used in our statistical analysis
included 490 PCa samples, which is greater than the
sample number in Zhang’s clinical cohort (n= 180).
Using this larger data set, we demonstrated that high-
miR-188-5p and/or low-UBE2I expression was sig-
niﬁcantly associated with aggressive PCa progression and
poor patient prognosis. Third, both groups used the same
PCa cell lines (PC3 and LNCaP) to perform a series of
in vitro and in vivo functional experiments. However,
different ﬁndings were obtained, which may be due to the
heterogeneity of cancer cells in different experimental
platforms. Therefore, further large-scale validations are
needed in the future.
We also determined the downstream effectors of the
miR-193a-5p/TP73 and miR-188-5p/UBE2i axes.
CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I sig-
naling was identiﬁed as a bottleneck in the miRNA-
mediated gene expression regulatory network of PCa,
which represents key interactions with surprising func-
tional and dynamic properties29. Based on the molecular
interactions and the implications of this signaling in
cancer11–20,30, we illustrated a biomodule of miR-193a-5p-
and miR-188-5p-regulated CCND1-RNASEL-CDKN1A-
TP73-MDM2-UBE2I signaling in Fig. 1b. Our experi-
mental validations further conﬁrmed the regulatory
effects of miR-193a-5p and miR-188-5p on this signaling
axis at both mRNA and protein levels.
Collectively, this integrated analysis of an miRNA-
mediated gene expression regulatory network reveals the
potential roles of miR-193a-5p/TP73 and miR-188-5p/
UBE2i negative regulation pairs in PCa. Our data showed
that miR-193a-5p and miR-188-5p targeted TP73 and
UBE2I respectively at mRNA and protein level, suggesting
that the two miRNAs may not work at the translational
level throughout a DICER mechanism. In addition to the
signiﬁcant clinical relevance, miR-193a-5p- and miR-188-
5p-regulated CCND1-RNASEL-CDKN1A-TP73-MDM2-
UBE2I signaling may be a novel regulatory biomodule
within prostate carcinogenesis. However, there are several
limitations in the clinical cohort using in this study. For
(see ﬁgure on previous page)
Fig. 7 Western blot analysis indicated that CCND1, RNASEL, CDKN1A and MDM2 function as the downstream effectors of the miR-193a-
TP73 and miR-188-UBE2I axes at a protein level. a Relative protein expression levels of TP73, CCND1, RNASEL, CDKN1A, and MDM2 in LNCaP and
PC3 cells transfected with miR-193a/NC-mimics. b Relative protein expression levels of UBE2I, CCND1, RNASEL, CDKN1A, and MDM2 in LNCaP and
PC3 cells transfected with miR-188/NC-mimics. c Relative protein expression levels of TP73, CCND1, RNASEL, CDKN1A, and MDM2 in LNCaP and PC3
cells transfected with TP73/NC-expression vector. d Relative protein expression levels of UBE2I, CCND1, RNASEL, CDKN1A, and MDM2 in LNCaP and
PC3 cells transfected with UBE2I/NC-expression vector. The data are representative of at least three independent experiments and are presented as
the mean ± s.e.m. *P < 0.05, compared with the normal control group; **P < 0.01, compared with the normal control group
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example, only 71 in 490 (14.5%) PCa patients occurred
BCR; Only 10 in 490 (2.0%) patients died of PCa during
the follow-up of overall survival. The imbalance of the
feature distribution in this TCGA cohort might lead to the
minor clinical relevance of the two miRNA/target pairs.
Therefore, further prognostic evaluation based on other
independent and large cohorts in compliance with sta-
tistical standard are required.
Methods
miRNA-mediated gene expression regulatory network
analysis
A miRNA-mediated gene expression regulatory net-
work was constructed based on the links between miR-
NAs and the corresponding putative target genes and the
interactions among the putative target genes (Supple-
mentary File S1—sections 2–4).
Four topological features of nodes, including ‘Degree,’
‘Node betweenness,’ ‘Closeness’ and ‘K coreness,’ and one
topological feature of edges (links among nodes), namely,
‘Edge betweenness,’ were calculated to assess the topo-
logical importance of nodes and edges in the miRNA-
mediated gene expression regulatory network. Each fea-
ture mentioned above is deﬁned in Supplementary File S1
—section 5.
In addition, functional modularity was analyzed using
the Markov clustering algorithm to identify nodes that are
highly interconnected within the miRNA-mediated gene
expression regulatory network and are generally involved
in the same functional modules or biological pathways.
TCGA miRNA/mRNA data sets
The expression proﬁles of miRNAs and mRNAs and
clinical information for a cohort of 490 patients with
primary PCa were retrieved from The Cancer Genome
Atlas (TCGA, Provisional, http://cancergenome.nih.gov,
Supplementary Table S6). A language package for R was
used to perform data statistical analysis.
Survival analysis
Follow-up data of all patients with primary PCa were
collected from TCGA. The overall survival was calculated
from the date of surgery to the date of the last follow-up
or death. The biochemical recurrence (BCR)-free survival
was deﬁned as the interval between the time of the initial
surgery and the date of the ﬁrst occurrence of detectable
consecutive increases in PSA levels. The distant-
metastasis-free survival was determined as the interval
from the time of the initial surgery to the observation date
of metastatic lesions.
Cell culture
Two human PCa cell lines, LNCaP and PC3, were
purchased from the American Type Culture Collection
(Manassas, VA, USA) and cultured in RPMI 1640 med-
ium (HyClone, Los Angeles, CA, USA) supplemented
with 10% fetal bovine serum (GIBCO/Invitrogen, Carls-
bad, CA, USA), 2 mM L-glutamine, and antibiotics. A
normal human prostate epithelial cell line (PREC) was
purchased from Lonza Company and cultured in PrEGM
Bullet kit (Lonza, Allendale, NJ, USA) with antibiotics. All
cell lines were maintained at 37 °C in a humidiﬁed
chamber supplemented with 5% CO2.
Animals
All animal experiments were performed according to
the guidelines of the Institute for Laboratory Animal
Research at Guangzhou Medical University, Guangzhou,
P.R. China. BALB/c nude mice (4–5-week-old males) were
obtained from Guangdong Medical Laboratory Animal
Center and were housed ﬁve per cage in wire-top cages
with sawdust bedding in an isolated, clean, air-
conditioned room at a temperature of 25–26 °C, a rela-
tive humidity of ~50% and with a 12 h light cycle/day.
Cellular transfection
Commercial miR-188-5p mimics (miR-188-mimic, Cat.
No.: miR10005301-1-5), miR-193a-5p mimics (miR-193a-
mimic, Cat. No.: miR10000459-1-5), miRNA mimic con-
trol (NC-mimic, Cat. No.: miR01101-1-5), miR-188-5p
inhibitor (anti-miR-188, Cat. No.: miR20005301-1-5),
miR-193a-5p inhibitor (anti-miR-193a, Cat. No.:
miR20000459-1-5), and a nonspeciﬁc anti-miRNA control
(anti-NC, Cat. No.: miR02201-1-5) were purchased from
RiboBio (Guangzhou, China). The pCDNA3.1-UBE2i and
pCDNA3.1-TP73 vectors were generated by cloning the
ORFs of the UBE2i and TP73 genes into the pCDNA3.1
vector, performed by HYYMed (Guangzhou, China), and
the pCDNA3.1 backbone vector was used as a blank
control vector. These vectors were transfected into PCa
cells using Lipofectamine 2000 reagent (Invitrogen Life
Technologies, Carlsbad, CA, USA) according to the
manufacturer’s protocol.
Generation of the in vivo xenograft model
LNCaP cells transfected with miR-188-5p/miR-193a-5p,
miR-NC, anti-miR-188-5p/miR-193a-5p, or anti-NC len-
tivectors were used to construct the xenograft model of
PCa for the in vivo tumor formation assay, as described in
our previous studies5,6. Detailed information on model
construction and tumor volume calculation is provided in
Supplementary File S1—section 6.
Quantitative reverse transcription-PCR (qRT-PCR)
The qRT-PCR analyses for miRNAs and mRNAs in
different cells were performed as described in our pre-
vious studies5,6,31. The primer sequences are listed in
Supplementary Table S7.
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Western blotting
Western blot analysis was performed as described in our
previous studies5,6,31. Detailed information of the speciﬁc
antibodies is provided in Supplementary Table S8.
Luciferase reporter assay
Luciferase reporter assay was performed to conﬁrm
direct binding efﬁciency of miRNAs and the corre-
sponding target mRNA as described in our previous
studies5,6,31. Detailed information is provided in Supple-
mentary File S1—section 7.
Cell viability assay
Cell viability of PCa cells transfected with different
vectors was detected with a Cell Counting Kit-8 (CCK-8,
Cat No. C0037, Beyotime Biotechnology, Jiangsu, China)
assay according to the protocol described in our previous
studies5,6,32.
Cell invasion and migration assays
The cell invasion and migration abilities of PCa cells
transfected with different vectors were detected by the
transwell and the scratch wound-healing motility assays,
respectively, according to the protocol described in our
previous studies5,6,32.
Apoptosis assay
Cell apoptosis of PCa cells transfected with different
vectors was detected using the APC-conjugated Annexin
V (Annexin V-APC)/7-aminoactinomycin D (7-AAD) Kit
(Cat. No.: LK-AP104-60, Multi Sciences (Lianke) Biotech
Co., Ltd., Hangzhou, China) according to the protocol
described in our previous studies5,6,32.
Statistical analysis
SPSS version 13.0 for Windows (SPSS Inc., IL, USA)
was used for all statistical analyses in this study. All assays
were performed in triplicate. Continuous variables are
expressed as the mean± s.e.m. Differences in the qRT-
PCR and western blot data for different groups were
evaluated using the Wilcoxon signed-rank test. The
associations between miRNA/mRNA expression and
various clinicopathological features of PCa patients were
conﬁrmed by two biostatisticians with Fisher’s exact test
for any 2× 2 tables and the Pearson χ2-test for non-2× 2
tables. A Kaplan–Meier curve was used for the survival
analysis, and the Cox regression model was used for the
univariate and multivariate analyses. The Spearman cor-
relation was calculated between the expression levels of
miRNAs and the corresponding target mRNAs in PCa
tissues. Differences were considered signiﬁcant when the
p-value was <0.05.
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